SCID

SCID
Name	Severe combined immunodeficiency
Field	Immunology, Pediatrics
Symptoms	Recurrent infections, failure to thrive, chronic diarrhea
Complications	Opportunistic infections, vaccine-related disease
Onset	Infancy
Causes	Genetic mutations (e.g., IL2RG, ADA)
Diagnosis	Lymphocyte counts, genetic testing
Treatment	Hematopoietic stem cell transplantation, gene therapy, enzyme replacement
Frequency	~1 in 50,000 to 100,000 births (varies)

SCID

Severe combined immunodeficiency presents as a group of inherited disorders causing profound defects in T‑cell development and function, often with secondary B‑cell and natural killer cell abnormalities. Infants commonly show recurrent bacterial, viral, fungal, and opportunistic infections, failure to thrive, and absent vaccine responses; early recognition and definitive therapy dramatically alter outcomes. Management spans newborn screening, immunological workup, hematopoietic stem cell transplantation, targeted gene therapies, and supportive infectious disease care.

Signs and symptoms

Affected infants typically present in the first months of life with recurrent Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus bacterial infections, chronic Candida or Aspergillus fungal infections, severe Respiratory syncytial virus or Cytomegalovirus viral disease, and persistent diarrhea leading to failure to thrive. Opportunistic pathogens such as Pneumocystis jirovecii cause life‑threatening pneumonia, while vaccination with live vaccines like Bacillus Calmette–Guérin or Oral polio vaccine can produce disseminated disease. Physical findings may include absent lymphoid tissue, chronic dermatitis, and growth retardation noted during visits to pediatric centers such as Great Ormond Street Hospital or Boston Children's Hospital. Family history may reveal early infant deaths in pedigrees traced through records from institutions like Mayo Clinic or Johns Hopkins Hospital.

Causes and genetics

Genetic causes include mutations in the X‑linked gene encoding the common gamma chain (IL2RG), autosomal recessive defects in genes such as ADA, RAG1, RAG2, JAK3, and defects in recombination machinery reported in cohorts at Hospital for Sick Children and research consortia like the European Society for Immunodeficiencies. Historical molecular discoveries were reported in laboratories associated with National Institutes of Health and Cold Spring Harbor Laboratory. Population studies from countries including United Kingdom, United States, Israel, and Japan document variable allele frequencies and founder effects; genetic counseling often involves teams from American College of Medical Genetics or national newborn screening programs under ministries such as the Department of Health and Human Services.

Pathophysiology

Defective signaling through interleukin receptors (e.g., IL‑2, IL‑7) due to mutated gamma chain impairs thymic T‑cell maturation, as described in classic immunology texts used at Harvard Medical School and University of Oxford. ADA deficiency causes toxic metabolite accumulation with lymphotoxicity, elucidated in biochemical studies at institutions like Karolinska Institute. RAG mutations block V(D)J recombination, preventing diverse antigen receptor formation, a mechanism explored in collaborations involving Cold Spring Harbor Laboratory and Institute Pasteur. The net result is severe cellular immunodeficiency, loss of humoral responses mediated by B cells, and susceptibility to intracellular pathogens documented in cohort analyses from Centers for Disease Control and Prevention.

Diagnosis

Newborn screening using T‑cell receptor excision circle (TREC) assays implemented in programs led by Newborn Screening Translational Research Network and agencies such as Centers for Disease Control and Prevention flags low naive T‑cell output. Confirmatory testing includes lymphocyte subset enumeration by flow cytometry performed in clinical labs at Mayo Clinic Laboratories and genetic sequencing panels provided by companies collaborating with Genetics and Public Policy Center. Functional assays—lymphocyte proliferation to mitogens—and measurement of ADA enzyme activity are routinely employed, with diagnostic criteria refined through consensus meetings by groups such as the Primary Immune Deficiency Treatment Consortium.

Treatment and management

Definitive therapy is hematopoietic stem cell transplantation (HSCT) performed at transplant centers like Fred Hutchinson Cancer Center and Great Ormond Street Hospital, with improved survival when HLA‑matched sibling donors from registries such as Be The Match are available. Enzyme replacement therapy with polyethylene glycol‑modified ADA (PEG‑ADA) has been developed by biotechnology collaborations, while experimental gene therapies—using lentiviral or gammaretroviral vectors—have been trialed in programs at University College London and St. Jude Children's Research Hospital. Supportive measures include prophylactic antimicrobials per guidelines from Infectious Diseases Society of America and immunoglobulin replacement provided by blood services like Red Cross. Infection control and avoidance of live vaccines follow recommendations from agencies such as World Health Organization.

Prognosis and outcomes

Without curative therapy, infants face high mortality in the first year of life due to severe infections, a pattern documented in historical series from Johns Hopkins Hospital. Outcomes after HSCT have improved substantially, with long‑term survival reported in multicenter registries coordinated by the European Society for Blood and Marrow Transplantation and the Primary Immune Deficiency Treatment Consortium. Gene therapy trials have achieved immune reconstitution in many patients, though insertional mutagenesis risks identified in early trials prompted vector redesign overseen by regulatory bodies such as the U.S. Food and Drug Administration.

Epidemiology and screening

Estimated incidence ranges from about 1 in 50,000 to 1 in 100,000 live births, with variation documented in population studies from United States, Canada, Sweden, and Israel. Newborn screening adoption across states and countries has been driven by advocacy from foundations like the Immune Deficiency Foundation and policy recommendations from organizations such as the Advisory Committee on Heritable Disorders in Newborns and Children. Epidemiologic registries maintained by institutions including European Society for Immunodeficiencies and national health agencies enable assessment of screening impact and long‑term outcomes.

Category:Immunodeficiency